Cargando…

Change in the treatment strategy for pediatric Crohn's disease

Crohn's disease is characterized by chronic inflammation involving any portion of the gastrointestinal tract. Treating Crohn's disease is a major challenge for clinicians, as no curative therapy currently exists. Pediatric Crohn's disease is characterized by frequent relapses, a wide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Mi Jin, Choe, Yon Ho
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Pediatric Society 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005214/ https://www.ncbi.nlm.nih.gov/pubmed/21189967 http://dx.doi.org/10.3345/kjp.2010.53.9.830

Ejemplares similares

Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target
por: Kang, Ben, et al.
Publicado: (2018)

Efficacy of Combined Initial Treatment of Methotrexate with Infliximab in Pediatric Crohn’s Disease: A Pilot Study
por: Kim, Yoon-Zi, et al.
Publicado: (2023)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up
por: Lee, Yun Seok, et al.
Publicado: (2012)

Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy
por: Kim, Mi Jin, et al.
Publicado: (2015)

Upper gastrointestinal tract involvement is more prevalent in Korean patients with pediatric Crohn’s disease than in European patients
por: Kim, Eun Sil, et al.
Publicado: (2020)

Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn’s disease patients with secondary loss of response
por: Kim, Eun Sil, et al.
Publicado: (2023)

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
por: Kim, Eun Sil, et al.
Publicado: (2021)

Anti-Saccharomyces cerevisiae Antibody in Pediatric Crohn’s Disease Patients without Mucosal Healing Is a Useful Marker of Mucosal Damage
por: Kim, Mi Jin, et al.
Publicado: (2021)

Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
por: Kim, Eun Sil, et al.
Publicado: (2022)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
por: Song, Won Jae, et al.
Publicado: (2016)

Nutritional Therapy Strategies in Pediatric Crohn’s Disease
por: Verburgt, Charlotte M., et al.
Publicado: (2021)

Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
por: Choi, Jaeyoung, et al.
Publicado: (2018)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

How has the disease course of pediatric ulcerative colitis changed throughout the biologics era? A comparison with the IBSEN study
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Monitoring Thiopurine Metabolites in Korean Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Mi Jin, et al.
Publicado: (2014)

The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn’s Disease
por: Ha, Changhee, et al.
Publicado: (2020)

Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
por: Park, Sowon, et al.
Publicado: (2022)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Vedolizumab Is Safe and Efficacious for the Treatment of Pediatric-Onset Inflammatory Bowel Disease Patients Who Fail a Primary Biologic Agent
por: Choi, Sujin, et al.
Publicado: (2022)

Pediatric Magnetic Resonance Enterography: Focused on Crohn's Disease
por: Lee, So Mi, et al.
Publicado: (2015)

Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015)

Monitoring and Safety of Azathioprine Therapy in Inflammatory Bowel Disease
por: Kim, Mi Jin, et al.
Publicado: (2013)

Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease
por: Kim, Hyeon-A, et al.
Publicado: (2019)

Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
por: Chun, Ji Young, et al.
Publicado: (2013)

Nutritional Therapy in Pediatric Crohn’s Disease—Are We Going to Change the Guidelines?
por: Matuszczyk, Malgorzata, et al.
Publicado: (2021)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity
por: Kim, Eun Sil, et al.
Publicado: (2021)

Increased Demand for Therapeutic Drugs in Pediatric Ulcerative Colitis Patients With Extraintestinal Manifestations
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Korean Children and Adolescents with Crohn's Disease Are More Likely to Present with Perianal Fistulizing Disease at Diagnosis Compared to Their European Counterparts
por: Kang, Ben, et al.
Publicado: (2020)

Therapeutic Lymphatic Embolization in Pediatric Primary Intestinal Lymphangiectasia
por: Kwon, Yiyoung, et al.
Publicado: (2021)

Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
por: Kim, Mi Jin, et al.
Publicado: (2021)

Dietary Management in Pediatric Patients with Crohn’s Disease
por: Scarallo, Luca, et al.
Publicado: (2021)

Author Correction: COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity
por: Kim, Eun Sil, et al.
Publicado: (2021)

Evolving treatment strategies in Crohn’s disease
por: Shen, Bo
Publicado: (2023)

Impact of the histologic grade of acute gastrointestinal graft-versus-host disease on outcomes in pediatric patients treated with allogeneic hematopoietic stem cell transplantation
por: Kim, Eun Sil, et al.
Publicado: (2023)

Wasting condition as a marker for severe disease in pediatric Crohn's disease
por: Jin, Wook, et al.
Publicado: (2022)

Infliximab therapy in pediatric Crohn’s disease: a review
por: Parashette, Kalyan Ray, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fqp03ti0thtsatrjgb71150kit